Scarica l'app Stockscreener
28.64
2.32%
0.65
Dopo l'orario di chiusura:
28.51
-0.13
-0.45%
Precedente Chiudi:
$27.99
Aprire:
$26.69
Volume 24 ore:
8.39M
Relative Volume:
4.14
Capitalizzazione di mercato:
$2.56B
Reddito:
$288.07M
Utile/perdita netta:
$22.31M
Rapporto P/E:
202.26
EPS:
0.1416
Flusso di cassa netto:
$41.15M
1 W Prestazione:
-58.15%
1M Prestazione:
-58.90%
6M Prestazione:
-23.99%
1 anno Prestazione:
+30.78%
Intervallo 1D:
$26.31
$29.18
Intervallo di 1 settimana:
$22.31
$74.74
Portata 52W:
$21.91
$93.61
Liquidia Corp Stock (LQDA) Company Profile
Nome
Liquidia Corp
Settore
Telefono
919.328.4400
Indirizzo
419 DAVIS DRIVE, SUITE 100, MORRISVILLE, NC
Compare LQDA vs TAK, TEVA, HLN, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LQDA
Liquidia Corp
|
28.64 | 6.13B | 288.07M | 22.31M | 41.15M | 0.1416 |
TAK
Takeda Pharmaceutical Co Adr
|
17.86 | 60.23B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
39.53 | 45.71B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
8.80 | 40.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
69.69 | 29.36B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
541.70 | 20.39B | 3.17B | 1.29B | 1.01B | 27.09 |
Liquidia Corp Stock (LQDA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-20 | Iniziato | Wells Fargo | Overweight |
| 2025-08-15 | Ripresa | Jefferies | Buy |
| 2025-05-19 | Downgrade | Oppenheimer | Perform → Underperform |
| 2024-12-20 | Iniziato | Wells Fargo | Overweight |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-08-19 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-08-16 | Iniziato | Raymond James | Outperform |
| 2024-06-25 | Iniziato | Oppenheimer | Perform |
| 2024-01-05 | Reiterato | Needham | Buy |
| 2022-09-19 | Ripresa | Wedbush | Underperform |
| 2022-09-01 | Downgrade | Wedbush | Neutral → Underperform |
| 2022-07-22 | Iniziato | Ladenburg Thalmann | Buy |
| 2022-05-31 | Iniziato | BTIG Research | Buy |
| 2022-05-26 | Iniziato | BofA Securities | Buy |
| 2020-12-04 | Iniziato | H.C. Wainwright | Buy |
| 2020-11-20 | Downgrade | Wedbush | Outperform → Neutral |
| 2018-11-08 | Ripresa | Jefferies | Buy |
| 2018-09-05 | Iniziato | Wedbush | Outperform |
| 2018-08-20 | Iniziato | Jefferies | Buy |
| 2018-08-20 | Iniziato | Needham | Buy |
Mostra tutto
Liquidia Corp Borsa (LQDA) Ultime notizie
United Therapeutics Just Sent Liquidia Stock Lower After Patent Battle - Barchart.com
Analysts Are Bullish on Top Healthcare Stocks: Jade Biosciences (JBIO), Liquidia Technologies (LQDA) - theglobeandmail.com
Liquidia Shares Drop After Downgrades From Raymond James, BTIG - marketscreener.com
LQDA Stock On Track For Worst Week Ever As Analysts Say The Yutrepia Patent Loss Clouds Its Path - TradingView
LQDA Downgraded by Raymond James -- Price Target Lowered to $53. - GuruFocus
Liquidia Stock Plunges 57% on UTHR Patent Litigation Setback - Zacks Investment Research
Liquidia stock cut to Neutral at BTIG (LQDA:NASDAQ) - Seeking Alpha
Liquidia Stock Extends Slide Following US Court Ruling in Patent Dispute - Benzinga
UTHR Prevails in LQDA's Yutrepia Patent Dispute, Stock Up Nearly 13% - TradingView
United Therapeutics Won Its Patent War and Liquidia Collapsed - AOL.com
Liquidia (NASDAQ:LQDA) Shares Gap Down on Analyst Downgrade - MarketBeat
Liquidia Sinks Another 17% as BofA Cuts Target to $40 From $92 After Court Loss - Yahoo Finance
Liquidia Corporation Stock 12‑Month Price Target Cut to $84.43, Implies 179% Upside - TradingView
Liquidia (NASDAQ:LQDA) Stock Price Target Lowered at Needham & Company LLC - MarketBeat
United Therapeutics Stock Rises Following Federal Court Patent Victory Over Liquidia - Benzinga
Raymond James Downgrades Liquidia to Outperform From Buy, $53 Price Target - marketscreener.com
Liquidia Corp (LQDA) Leads September 2026 Healthcare Declines wi - GuruFocus
Raymond James downgrades Liquidia stock rating on patent ruling - Investing.com India
Liquidia Stock Analysis: Post-Ruling Impact and Price Oversold - The Cryptonomist
LQDA Downgraded by BTIG -- Rating Changed to Neutral - GuruFocus
Liquidia stock rating cut to neutral by BTIG on patent ruling - Investing.com UK
BTIG Downgrades Liquidia to Neutral From Buy - marketscreener.com
Why is Liquidia stock down 5% today? - Investing.com
LQDA Maintained by Needham -- Price Target Lowered to $72.00 - GuruFocus
United Therapeutics Surges 13% After Patent Victory Against Liquidia - citybiz
Needham maintains Buy rating on Liquidia, $72 price target - TradingView
United Therapeutics Wins Patent Lawsuit Against Liquidia - marketscreener.com
Liquidia (LQDA) Dropped, So What Is Behind The Sudden Shift? - Simply Wall Street
Why is Liquidia stock plunging? Yutrepia patent case explained - The Economic Times
United Therapeutics Soars 13% as Court Rules Yutrepia Infringes Its Patent - TIKR.com
Liquidia Corp. Shares Edge Higher After HoursUnited Therapeutics (NASDAQ:UTHR), Liquidia (NASDAQ:LQDA) - Benzinga
Liquidia CEO Roger Jeffs Says Demand For Inhaled Lung Disease Drug Is Growing Amid Q2 Revenue Beat - Stocktwits
United Therapeutics Corporation Prevails in Patent Litigation Against Liquidia - FinancialContent
Liquidia Corp (LQDA) Shares Fall 57.2% -- What GF Score of 70 Te - GuruFocus
Liquidia Loses Bid to Nix United Therapeutics Lung-Drug Patent - Bloomberg Law News
Liquidia slumps after US court rules for United Therapeutics in patent fight - SRN News
Liquidia Corp (LQDA) Shares Plunge Over 57% Following Patent Rul - GuruFocus
Liquidia plunges 57% on litigation update (LQDA:NASDAQ) - Seeking Alpha
United Therapeutics jumps 13% on court ruling (UTHR:NASDAQ) - Seeking Alpha
Why is Liquidia share price falling by nearly 50% today? US federal court ruling linked to lung drug Yutre - The Economic Times
Liquidia Gets Hit By Delaware Patent Ruling - Finimize
Why Is United Therapeutics (UTHR) Stock Rocketing Higher Today - TradingView
LQDA Stock Eyes Worst Day Ever After Judge Upholds Two UTHR Patent Claims - Yahoo Finance
Liquidia options activity surges after patent ruling sinks LQDA 48% - Investing.com
Why is Liquidia stock cratering today? By Investing.com - Investing.com Nigeria
LQDA versus ALKS: Which Biotech Stock Is the Better Buy Now? - theglobeandmail.com
Liquidia loses patent infringement case on two claims By Investing.com - Investing.com Nigeria
Liquidia: Bullish On Their Growth Potential Despite YUTREPIA's Legal Tail Risk - Seeking Alpha
Why is Liquidia stock cratering today? - Investing.com
Liquidia shares crater after court rules for United Therapeutics - Investing.com
Liquidia (LQDA) Shares Drop 52% After Delaware Court Patent Ruli - GuruFocus
Liquidia Corp Azioni (LQDA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Liquidia Corp Azioni (LQDA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| SINGH RAMAN | Director |
Sep 14 '26 |
Option Exercise |
9.31 |
8,468 |
78,799 |
53,105 |
| SINGH RAMAN | Director |
Sep 11 '26 |
Sale |
68.62 |
9,024 |
619,210 |
44,637 |
| SINGH RAMAN | Director |
Sep 14 '26 |
Sale |
66.16 |
8,468 |
560,243 |
44,637 |
1.15%
5.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):